CL2016003293A1 - Inhibidores de mnk y método relacionado al mismo - Google Patents

Inhibidores de mnk y método relacionado al mismo

Info

Publication number
CL2016003293A1
CL2016003293A1 CL2016003293A CL2016003293A CL2016003293A1 CL 2016003293 A1 CL2016003293 A1 CL 2016003293A1 CL 2016003293 A CL2016003293 A CL 2016003293A CL 2016003293 A CL2016003293 A CL 2016003293A CL 2016003293 A1 CL2016003293 A1 CL 2016003293A1
Authority
CL
Chile
Prior art keywords
formula
pharmaceutically acceptable
composite
compositions
related method
Prior art date
Application number
CL2016003293A
Other languages
English (en)
Inventor
Siegried H Reich
Paul A Sprengeler
Stephen E Webber
Alan Xin Xiang
Justin Thomas Ernst
Original Assignee
Effector Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effector Therapeutics Inc filed Critical Effector Therapeutics Inc
Publication of CL2016003293A1 publication Critical patent/CL2016003293A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE ACUERDO CON LA FÓRMULA (I):</p> <p>* incluir figura de estructura de pagina 396 de hoja técnica , documento completo.</p> <p>O UN ESTEREOISÓMERO, TAUTÓMERO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, EN LA QUE R1, R2, R3, R4A, R4B, R5, R6, R7, R8, W1, W2, Y N SON COMO SE DEFINEN EN LA PRESENTE. TAMBIÉN SE DESCRIBEN COMPOSICIONES FARMACÉUTICAMENTE ACEPTABLES DE COMPUESTOS DE LA FÓRMULA (I) ASÍ COMO MÉTODOS PARA UTILIZAR LOS COMPUESTOS DE LA FÓRMULA (I) Y LAS COMPOSICIONES FARMACÉUTICAMENTE ACEPTABLES DE COMPUESTOS DE LA FÓRMULA (I) COMO INHIBIDORES DE MNK ASÍ COMO AGENTES TERAPÉUTICOS PARA EL TRATAMIENTO DE ENFERMEDADES TALES COMO EL CÁNCER.</p>
CL2016003293A 2014-06-25 2016-12-22 Inhibidores de mnk y método relacionado al mismo CL2016003293A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462017112P 2014-06-25 2014-06-25

Publications (1)

Publication Number Publication Date
CL2016003293A1 true CL2016003293A1 (es) 2017-09-08

Family

ID=53724447

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003293A CL2016003293A1 (es) 2014-06-25 2016-12-22 Inhibidores de mnk y método relacionado al mismo

Country Status (24)

Country Link
US (6) US9382248B2 (es)
EP (2) EP3521289B1 (es)
JP (2) JP6615797B2 (es)
KR (1) KR102460389B1 (es)
CN (2) CN110183449B (es)
AU (1) AU2015279984B2 (es)
BR (1) BR112016029916B1 (es)
CA (1) CA2953365C (es)
CL (1) CL2016003293A1 (es)
CO (1) CO2017000399A2 (es)
DK (2) DK3160966T3 (es)
EA (1) EA033920B1 (es)
ES (2) ES2967536T3 (es)
FI (1) FI3521289T3 (es)
IL (1) IL249557B (es)
MX (1) MX2016017030A (es)
MY (1) MY189363A (es)
NZ (1) NZ728007A (es)
PE (1) PE20170321A1 (es)
PH (1) PH12016502504A1 (es)
SG (2) SG11201610511YA (es)
TW (1) TWI713455B (es)
WO (1) WO2015200481A1 (es)
ZA (1) ZA201700241B (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11878015B2 (en) 2017-02-14 2024-01-23 Effector Therapeutics Inc. Piperidine-substituted Mnk inhibitors and methods related thereto
US11952375B2 (en) 2018-10-24 2024-04-09 Effector Therapeutics Inc. Crystalline forms of Mnk inhibitors

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
AU2016252038B2 (en) * 2015-04-20 2021-08-12 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
US10112955B2 (en) 2015-10-29 2018-10-30 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
JP6888006B2 (ja) 2015-10-29 2021-06-16 イーフェクター セラピューティクス， インコーポレイテッド Ｍｎｋ１およびｍｎｋ２を阻害するピロロ−、ピラゾロ−、イミダゾ−ピリミジンおよびピリジン化合物
US10000487B2 (en) 2015-11-20 2018-06-19 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
WO2017117052A1 (en) * 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
JP7105797B2 (ja) 2016-11-28 2022-07-25 プラクシス プレシジョン メディシンズ， インコーポレイテッド 化合物及びその使用方法
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
CA3050599A1 (en) * 2017-01-20 2018-07-26 Bayer Pharma Aktiengesellschaft Substituted imidazopyridinpyrimidines
TW201831479A (zh) 2017-01-20 2018-09-01 德商拜耳製藥公司 經取代二氫咪唑并吡啶二酮
WO2018148745A1 (en) * 2017-02-13 2018-08-16 Praxis Precision Medicines , Inc. Compounds and their methods of use
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
CA3064000A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
WO2019035951A1 (en) 2017-08-15 2019-02-21 Praxis Precision Medicines, Inc. COMPOUNDS AND THEIR METHODS OF USE
AU2018352695A1 (en) 2017-10-19 2020-05-28 Effector Therapeutics, Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2
MX2020012838A (es) 2018-05-30 2021-07-16 Praxis Prec Medicines Inc Moduladores de los canales ionicos.
WO2020108619A1 (zh) * 2018-11-30 2020-06-04 上海迪诺医药科技有限公司 Mnk抑制剂
CN111484494B (zh) * 2019-01-29 2022-09-13 诺沃斯达药业(上海)有限公司 抑制mnk1和mnk2的多环化合物
EP3972593A4 (en) * 2019-05-23 2023-06-28 Board of Regents, The University of Texas System Inhibitor of mnk for the treatment of neuropathic pain
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
TW202114681A (zh) 2019-07-02 2021-04-16 美商ｅＦＦＥＣＴＯＲ醫療公司 轉譯抑制劑及其用途
BR112021026682A2 (pt) 2019-07-02 2022-03-15 Effector Therapeutics Inc Compostos e métodos para inibir eif4e
US20220251085A1 (en) * 2019-07-21 2022-08-11 University Of Virginia Patent Foundation Cysteine binding compositions and methods of use thereof
EP4063364A4 (en) * 2019-11-18 2023-12-13 Jumbo Drug Bank Co., Ltd. PYRROLOTRIAZINE COMPOUNDS ACTING AS MNK INHIBITORS
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
IL299512A (en) * 2020-06-30 2023-02-01 4E Therapeutics Inc pyridine-1,5 - discussions that suppress MNK and methods of using them
WO2022038563A1 (en) * 2020-08-20 2022-02-24 Hepagene Therapeutics (HK) Limited Mnk inhibitors
US11925642B2 (en) 2020-10-08 2024-03-12 Board Of Regents, The University Of Texas System Regulation of eIF4E activity for migraine therapy
EP4335850A1 (en) * 2021-05-08 2024-03-13 Jumbo Drug Bank Co., Ltd. Salt form of pyrrolotriazine compound, crystal form thereof, and preparation method therefor
WO2023278686A1 (en) * 2021-06-30 2023-01-05 4E Therapeutics, Inc. Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use
CA3228265A1 (en) * 2021-08-05 2023-02-09 4E Therapeutics, Inc. Methods of treating migraine with mnk inhibitors
CN114736205B (zh) * 2022-03-31 2023-03-03 武汉九州钰民医药科技有限公司 化合物Tomivosertib的制备方法
CN114671869B (zh) * 2022-03-31 2023-06-30 武汉九州钰民医药科技有限公司 化合物Tomivosertib的合成方法
CN114853756B (zh) * 2022-03-31 2023-03-28 武汉九州钰民医药科技有限公司 化合物Tomivosertib的制备工艺

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491144A (en) 1991-05-30 1996-02-13 Ciba-Geigy Corporation Substituted diaminophthalimides and analogues
US9357797B2 (en) * 1999-11-06 2016-06-07 Janmarie Hornack Dietary supplement containing alkaline electrolyte buffers
JP4216709B2 (ja) * 2001-06-05 2009-01-28 リリー アイコス リミテッド ライアビリティ カンパニー Ｐｄｅ５阻害剤としてのテトラ環状化合物
TWI301760B (en) 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
JP2009509921A (ja) 2005-08-12 2009-03-12 アストラゼネカ アクチボラグ 置換イソインドロン類及び代謝調節型グルタミン酸受容体増強剤としてのその使用
BRPI0713328A2 (pt) * 2006-06-22 2012-10-30 Biovitrum Ab derivados de piridina e pirazina como inibidores de cinase mnk
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
DK2134689T3 (da) 2007-03-16 2014-06-30 Scripps Research Inst Inhibitorer af fokal adhæsionskinase
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
JP2009173629A (ja) 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
CA2735361A1 (en) * 2008-08-26 2010-03-04 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
EP2462123B1 (en) 2009-08-04 2013-10-02 Merck Sharp & Dohme Corp. 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
US9381177B2 (en) 2010-10-01 2016-07-05 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
AR084044A1 (es) 2010-11-30 2013-04-17 Pharmasset Inc Compuestos 2’-espiro-nucleosidos
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US9447087B2 (en) 2011-09-23 2016-09-20 University Of Utah Research Foundation Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders
PE20141404A1 (es) 2011-12-30 2014-10-28 Hanmi Pharm Ind Co Ltd Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
AU2013239816B2 (en) 2012-03-29 2017-08-24 G1 Therapeutics, Inc. Lactam kinase inhibitors
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
CA2873971A1 (en) * 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyrimidines
TW201412740A (zh) * 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
EP2917185B1 (en) * 2012-11-09 2017-05-10 Evotec International GmbH Sulfoximine substituted quinazolines for pharmaceutical compositions
GB2508652A (en) 2012-12-07 2014-06-11 Agency Science Tech & Res Heterocyclic piperazine derivatives
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
JP2016509036A (ja) 2013-02-20 2016-03-24 バイエル・ファルマ・アクティエンゲゼルシャフト Ｍｋｎｋ１阻害剤としての置換イミダゾ［１，２−ｂ］ピリダジン
TW201605867A (zh) 2013-11-20 2016-02-16 拜耳製藥公司 噻吩并嘧啶
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
EA201791363A1 (ru) * 2014-12-19 2018-01-31 Байер Фарма Акциенгезельшафт Пиразолопиридинамины в качестве ингибиторов mknk1 и mknk2
US10112955B2 (en) 2015-10-29 2018-10-30 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
JP6888006B2 (ja) 2015-10-29 2021-06-16 イーフェクター セラピューティクス， インコーポレイテッド Ｍｎｋ１およびｍｎｋ２を阻害するピロロ−、ピラゾロ−、イミダゾ−ピリミジンおよびピリジン化合物
GB201520500D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
US10000487B2 (en) 2015-11-20 2018-06-19 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
GB201520499D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11878015B2 (en) 2017-02-14 2024-01-23 Effector Therapeutics Inc. Piperidine-substituted Mnk inhibitors and methods related thereto
US11952375B2 (en) 2018-10-24 2024-04-09 Effector Therapeutics Inc. Crystalline forms of Mnk inhibitors

Also Published As

Publication number Publication date
CN106795162A (zh) 2017-05-31
ES2728201T3 (es) 2019-10-22
CN106795162B (zh) 2019-07-16
JP2017519782A (ja) 2017-07-20
DK3521289T3 (da) 2024-01-15
WO2015200481A8 (en) 2016-06-30
IL249557B (en) 2021-10-31
CA2953365C (en) 2023-08-08
US9382248B2 (en) 2016-07-05
KR20170023145A (ko) 2017-03-02
FI3521289T3 (fi) 2024-01-09
AU2015279984B2 (en) 2019-12-05
EP3160966A1 (en) 2017-05-03
JP6979439B2 (ja) 2021-12-15
EP3521289B1 (en) 2023-10-25
US20180085368A1 (en) 2018-03-29
BR112016029916A2 (pt) 2017-08-22
US20190209560A1 (en) 2019-07-11
ES2967536T3 (es) 2024-04-30
IL249557A0 (en) 2017-02-28
CN110183449B (zh) 2022-08-19
CN110183449A (zh) 2019-08-30
DK3160966T3 (da) 2019-05-27
WO2015200481A1 (en) 2015-12-30
US20170266185A1 (en) 2017-09-21
BR112016029916B1 (pt) 2023-12-12
US9669031B2 (en) 2017-06-06
PE20170321A1 (es) 2017-04-05
CO2017000399A2 (es) 2017-04-28
TW201613918A (en) 2016-04-16
MY189363A (en) 2022-02-07
ZA201700241B (en) 2022-05-25
EP3521289A1 (en) 2019-08-07
JP6615797B2 (ja) 2019-12-04
TWI713455B (zh) 2020-12-21
CA2953365A1 (en) 2015-12-30
SG10201811384TA (en) 2019-01-30
SG11201610511YA (en) 2017-01-27
US20210338673A1 (en) 2021-11-04
EA201790078A1 (ru) 2017-05-31
EA033920B1 (ru) 2019-12-10
US20150376181A1 (en) 2015-12-31
EP3160966B1 (en) 2019-02-27
KR102460389B1 (ko) 2022-10-27
US20160317536A1 (en) 2016-11-03
JP2020063251A (ja) 2020-04-23
US9814718B2 (en) 2017-11-14
NZ728007A (en) 2023-03-31
PH12016502504A1 (en) 2017-04-10
AU2015279984A1 (en) 2017-01-19
MX2016017030A (es) 2017-09-11

Similar Documents

Publication Publication Date Title
CL2016003293A1 (es) Inhibidores de mnk y método relacionado al mismo
CL2017001572A1 (es) Compuestos de triazolopirimidina y usos de los mismos.
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CU24392B1 (es) Compuestos y composiciones para inducir condrogénesis
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CO2017004649A2 (es) Esteroides neuroactivos para trastornos del snc
CO2017001884A2 (es) Polimorfos de selinexor
UY36308A (es) Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CL2012002782A1 (es) Compuestos derivados de pirazol-4-il-heterociclil-carboxamida, inhibidores de los trastornos mediados por las quinasas pim-1, pim-2 y pim-3; composición farmacéutica; mètodo de tratamiento; y su uso para el tratamiento del càncer, trastornos inmunes, enfermedades cardiovasculares e infecciones virales , entre otros.
CL2016002245A1 (es) Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
ECSP18003372A (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
ECSP17007336A (es) Compuestos de imidazopiridazina
PE20170088A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
NI201600149A (es) Cromeno y 1,1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gamma-secretasa
NI201800071A (es) Compuestos de isoindol
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CL2017000040A1 (es) Inhibidores de aldosterona sintasa.
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
AR109328A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CL2017000242A1 (es) Compuestos de imidazopiridazina
AR109850A2 (es) Métodos para tratar infecciones por el virus filoviridae
GT201500232A (es) Compuestos de azabencimidazol como inhibidores de las isozimas pde4 para el tratamiento de cns y otros trastornos